Genmab A/S (LON: 0MGB)
London
· Delayed Price · Currency is GBP · Price in DKK
1,544.07
+18.34 (1.20%)
At close: Jan 22, 2025
Genmab Employees
Genmab had 2,204 employees as of December 30, 2023. The number of employees increased by 544 or 32.77% compared to the previous year.
Employees
2,204
Change (1Y)
544
Growth (1Y)
32.77%
Revenue / Employee
840.37K GBP
Profits / Employee
199.12K GBP
Market Cap
10.87B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
Shell | 103,000 |
AstraZeneca | 89,900 |
HSBC Holdings | 220,861 |
Unilever | 128,377 |
Rio Tinto Group | 57,000 |
RELX PLC | 36,500 |
BP p.l.c. | 87,800 |
British American Tobacco p.l.c. | 46,725 |
Genmab News
- 19 days ago - Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Genmab A/S: Circling Back On This Complicated Story - Seeking Alpha
- 6 weeks ago - Genmab to Hold 2024 R&D Update and ASH Data Review Meeting - GlobeNewsWire
- 6 weeks ago - Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) - Business Wire
- 6 weeks ago - Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis - Business Wire
- 6 weeks ago - Genmab Is Too Attractive To Ignore - Seeking Alpha
- 6 weeks ago - Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) - Business Wire
- 7 weeks ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire